517 results on '"Stamatatos, Leonidas"'
Search Results
2. Continuous germinal center invasion contributes to the diversity of the immune response
3. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies
4. Correction: Germinal center–dependent and –independent memory B cells produced throughout the immune response
5. Antigen affinity and site of immunization dictate B cell recall responses
6. Continuous germinal center invasion contributes to the diversity of the immune response
7. Adjuvants influence the maturation of VRC01-like antibodies during immunization
8. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
9. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
10. Structural basis for germline antibody recognition of HIV-1 immunogens.
11. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses.
12. Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity
13. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
14. Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response
15. CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals
16. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies
17. CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals
18. The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection
19. Adjuvants influence the maturation of VRC01-like antibodies during immunization
20. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
21. Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
22. Germline‐targeting immunogens
23. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
24. Blood Monocytes Harbor HIV Type 1 Strains with Diversified Phenotypes including Macrophage-Specific CCR5 Virus
25. The Human Immunodeficiency Viruses
26. Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy
27. 923. Respiratory Syncytial and Parainfluenza Virus Infection Increase the Risk of Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients
28. Fusion of Influenza, Sendai and Simian Immunodeficiency Viruses with Cell Membranes and Liposomes
29. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
30. An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
31. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
32. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
33. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
34. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
35. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
36. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
37. HIV ANTIBODIES: Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies
38. ENVELOPE-SPECIFIC TFH RESPONSES AND CROSS-NEUTRALIZING ANTIBODIES DEVELOP CONCOMITANTLY IN RHESUS MACAQUES CO-IMMUNIZED WITH HIV ENVELOPE DNA AND PROTEIN: ABSTRACT #40
39. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
40. Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 – 2021/03) Using a Statistical Learning Strategy
41. Germinal center–dependent and –independent memory B cells produced throughout the immune response
42. Designed proteins assemble antibodies into modular nanocages
43. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
44. Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy
45. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
46. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
47. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects
48. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials
49. Designed proteins assemble antibodies into modular nanocages
50. Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.